drugset
drugset / Trial / NCT00526968

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

NCT00526968 ↗

Phase 1 Completed 19 enrolled Evotec Neurosciences GmbH Richmond Pharmacology Limited · collab
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of this study is to investigate the neurophysiological changes following single doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male subjects.

Timeline

Start
2007-09
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject EVT 101 Small molecule 8 mg Oral
Subject EVT 101 Small molecule 15 mg Oral

Indications

No indication recorded.